1 Blockbuster Challenge for Drug Stocks

Before you go, we thought you'd like these...
Before you go close icon

The following video is from today's MarketFoolery podcast, in which host Chris Hill, along with Charly Travers, Jason Moser, and Joe Magyer, discuss the latest business news. Shares of Eli Lilly finished up nearly 3% after second-quarter earnings came in better than expected. The drugmaker also raised guidance for the full year. But with some of its key drugs about to come off patent, does Eli Lilly have enough in the pipeline to keep shareholders happy? Is the era of blockbuster drugs over for the likes of big drug companies like Pfizer and Bristol-Myers Squibb? In this segment, the guys analyze the challenge for the big drug companies as well as for smaller ones like Elan.

For investors seeking dividend-paying stocks trading at bargain-basement prices, just check out The Motley Fool's free report "2 Dirt Cheap Stocks With HUGE Dividends." You can get analysis of a market leader in payment systems and a high-yielding energy company by accessing this report. It won't be available forever, so simply click here -- it's free.

The article 1 Blockbuster Challenge for Drug Stocks originally appeared on Fool.com.

Chris Hillowns shares of Johnson & Johnson and Pfizer. The Motley Fool owns shares of Johnson & Johnson.Motley Fool newsletter serviceshave recommended buying shares of Johnson & Johnson and Pfizer and creating a diagonal call position in Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. Try any of our Foolish newsletter servicesfree for 30 days. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners